90 results about "Coenocyte" patented technology

The present invention provides a system for enhancing clearance or destruction of undesirable cells or noncellular molecular entities by tagging such cells or noncellular molecular entities with a marker that targets the cells or noncellular molecular entities for phagocytosis (phagocytic marker). The target cells can be, for example, endothelial cells, tumor cells, leukocytes, or virus-infected cells. In certain embodiments of the invention the tagging is accomplished by administering a composition comprising an antibody or ligand linked to the phagcytotic marker, wherein the antibody or ligand binds to a cell type specific marker present on or in the cell surface of a target cell. In preferred embodiments of the invention, the phagocytic marker comprises phosphatidylserine or a group derived from phosphatidylserine, thrombospondin-1, annexin I, or a derivative of any of these.

Extracts from plant material, or semi-purified/purified molecules or compounds prepared from the extracts that demonstrate the ability to modulate one or more cellular activities are provided. The extracts are capable of slowing down, inhibiting or preventing cell migration, for example, the migration of endothelial cells or neoplastic cells and thus, the use of the extracts to slow down, inhibit or prevent abnormal cell migration in an animal is also provided. Methods of selecting and preparing the plant extracts and methods of screening the extracts to determine their ability to modulate one or more cellular activity are described. The purification or semi-purification of one or more molecules from the described extracts is also contemplated as well as the use of these molecules, alone or in combination with an extract, to slow down, inhibit or prevent abnormal cell migration in an animal.

The invention discloses a construction method and application of a retinal neovascularization disease model, and relates to the field of biotechnology. The construction method knocks out the Tmem30a gene sequence in the genome of the target animal vascular endothelial cells, so that the target animal exhibits the typical retinal neovascularization disease characteristics. The target animal can beused as a model of retinal neovascularization disease, which can help to clarify the pathogenesis and mechanism of retinal neovascularization disease, and provide a new target for the treatment or prevention of retinal neovascularization disease.

The invention discloses a decellularized method for cornea. The decellularized method includes the following steps that (A), the picked animal cornea is placed in water, vibration treatment is carried out, and an epithelial layer falls off accordingly; (B), the cornea is placed in decellularized reagents for vibration treatment; (C), the cornea is placed in water for vibration treatment; (D), the step B and the step C are repeated alternately so that stroma cells and endothelial cells can fall off, wherein the decellularized reagents contain NaCl and EDTA. According to the decellularized method, the epithelial layer of the cornea and immunogen cellular constituents can be removed rapidly and tenderly, and therefore undamaged decellularized cornea ground substances can be obtained and have good biocompatibility and anti-degradation capacity.

The invention relates to platycodon grandiflorum polysaccharide extracted from rhizome of platycodon grandiflorum, a degradation product of the polysaccharide, a method for extracting the platycodon grandiflorum polysaccharide from the rhizome of the platycodon grandiflorum, a method for preparing the degradation product of the platycodon grandiflorum polysaccharide, and application of the platycodon grandiflorum polysaccharide and the degradation product thereof to preparing a medicine for treating anti-tumour cell angiogenesis diseases. The structure of the platycodon grandiflorum polysaccharide disclosed by the invention is (1->4)-alpha-D- pyranose homogalacturonan, has the polymerization degree of 15-100, the corresponding molecular weight of 2.0-18.0 kD, and the specific rotation of [alpha]D19+125 DEG (c0.05, H2O), and is represented by the following structural formula described in the specification. The molecular weight range of a degradation product obtained by partial acid hydrolysis of the platycodon grandiflorum pectin polysaccharide is 1.4-3.0 kDa. Vivo experiments prove that the platycodon grandiflorum polysaccharide can obviously inhibit lumen generation function of a human microvascular endothelial cell (HMEC-1) and is hopefully used as a novel anti-tumour medicine for inhibiting the growth of a solid tumour by inhibiting angiogenesis.

The invention relates to a medicine for in vitro hemostasis and a preparation method of the medicine. The in vitro injury bleeding conditions frequently occur in life; some in vitro injury bleeding conditions are caused by chance; some in vitro injury bleeding conditions are generated by combination with internal causes of the organism; the bleeding is caused by vascular permeability increase of postcapillary venule, capillary vessels and precapillary arteriole; blood leaks out of a lumen through an expanded endothelial cell clearance and a damaged vascular basement membrane, for example, finger injury bleeding, toe injury bleeding, skin scratch bleeding and the like. The medicine is prepared by combining the following raw materials: cirsium japonicum, cuttle bone, herba cirsii, cutch, sanguisorba officinalis, dragon blood, ramie root, loofah sponge, sophora japonica, rheum officinale, puffball, hairyvein agrimony, shrubalthea bark, rhizoma bletillae, alumen, crinis trachycarpi, coptis chinensis, folium artemisiae argyi, indigo naturalis, panax notoginseng, carbonized hair, pericarpium granati, cattail pollen, dark plum, ophicalcite, mongolian snake gourd roots, selaginella tamariscina, halloysitum rubrum, schizonepeta and cacumen biotae. The raw materials are combined to generate the synergistic effect in efficacy, so that in vitro injury bleeding can be effectively treated.

Provided is a means for reconstructing tissues and organs having mature functions. The method for producing tissues and organs is characterized by co-culturing organ cells with vascular endothelial cells and undifferentiated mesenchymal cells, producing an organ bud, and transplanting the same into a non-human animal, after which the tissue or organ derived from the transplanted organ bud is extracted from the non-human animal.

The invention discloses a preparation for producing a COVID-19 antibody after oral administration and a preparation method of the preparation. Attenuated salmonella typhimurium is used as a carrier todeliver DNA vaccine, the preparation effectively reaches intestinal tract and delivers DNA vaccine to intestinal endothelial cells with low mammalian toxicity infection through oral enteric-coated capsules, bacteria is phagocytosed through macrophages, and specific molecules COVID-19-S is expressed to be recognized by immune cells, so that the immune effect of specific antibodies in mammals (mice, humans and other mammals) neutralizing COVID-19-S protein is achieved.

The invention discloses an inhibitor for inhibiting the expression of MBD2 and application thereof, and relates to an inhibitor capable of inhibiting the expression of methylated CpG binding domain protein 2 in vivio and in vitro. The inhibitor comprises a nucleic acid molecule, a genetic structure, an siRNA molecule and a compound containing one or more of the nucleic acid molecule, the genetic structure and the siRNA molecule, and can be introduced into mammalian cells to inhibit the expression of the MBD2. The inhibitor for inhibiting the expression of the MBD2 is an siRNA, which has a nucleotide sequence in which the sense strand is 5'-GCAAGAGCGAUGUCUACUA-3' and the antisense strand is 5'-UAGUAGACAUCGCUCUUGC-3', or of which the 3' end is provided with two suspended basic groups tt, and has a nucleotide sequence in which the sense strand is 5'-GCAAGAGCGAUGUCUACUAtt-3' and the antisense strand is 5'-UAGUAGACAUCGCUCUUGCtt-3'. The application of the inhibitor in preventing and treating related diseases of vascular endothelial cell dysfunction provides a novel option for preparing medicaments or preparations for preventing and treating the related diseases of the vascular endothelial cell dysfunction by taking the MBD2 as a target.

The invention discloses a method for constructing a retinal neovascularization disease animal model by using a gene manipulation technology, a cultivation method and application, and relates to the technical field of gene editing. According to the construction method disclosed by the invention, the Ctnnnd1 gene in the vascular endothelial cells of the target animal is not expressed or the expression of the Ctnnd1 gene is inhibited by utilizing a gene manipulation technology. By means of the method, the animal model of the retinal neovascularization disease can be obtained, the variety of the animal model of the retinal neovascularization disease is enriched, more diversified model selections are provided for related research of the retinal neovascularization disease, and scientific research of the retinal neovascularization disease, development of related treatment drugs and the like are promoted.

An intracellular cytokine flow cytometry (CFC) assay was developed to measure CD3− (non-T) cell response to allo-Ags expressed on peripheral blood mononuclear cells (allo-CFC-PBMC) and/or endothelial cells (allo-CFC-EC) by detecting intracellular gamma-interferon (IFN_Y) production. The assay can be used to determine a likelihood of antibody mediated rejection in an individual. A method for using genetic screening to determine the likelihood of AMR is also disclosed.

The invention provides a p66Shc recombinant adenovirus vector. Homologous recombination in vitro of a human p66Shc fragment and a pAdeno X-CMV vector is realized by use of the gene engineering technology, and then competent bacteria are used for transformation to screen out correct recombinant adenoviruses; next, the recombinant adenoviruses are linearized and then used for transfecting HEK293A cells, and therefore, the recombinant adenoviruses are packaged and amplified largely in the HEK293A cells. After Hela cells are infected with the p66Shc recombinant adenovirus vectors, the growth and proliferation of the cells can be obviously inhibited; if human umbilical vein endothelial cells (HUVEC) are in infected with the p66Shc recombinant adenovirus vectors, no obvious growth inhibition effect is caused. The p66Shc recombinant adenovirus vector is expected to achieve a special growth inhibition effect on tumor cells.

The invention discloses bifidobacterium bifidum NX-7 and application of NX-7 in preparation of a medicine for treating ischemic diseases, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium bifidum NX-7 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No. 20115. The inactivated and non-inactivated fermentation supernatant and bacterial suspension of the bifidobacterium bifidum NX-7 can significantly promote the growth of the zebra fish subintestinal veins in vivo, significantly repair the injury of the zebra fish subintestinal veins induced by a vascular endothelial cell growth factor receptor inhibitor (PTK787), significantly promote the repair of the injury of the zebra fish tail fin, has the potential of promoting microcirculation regeneration and reconstruction, and shows the effect of being applied to in-vivo treatment of ischemic diseases. The bifidobacterium bifidum NX-7 disclosed by the invention has a huge potential application prospect in the aspect of treating ischemic diseases.

The invention relates to a method for preparing a cartilage angiogenesis inhibiting factor for a scalloped hammerhead shark. During preparation, Pro-Asp-Tyr-Lys-Phe-Lys is obtained through cartilage homogenate of the scalloped hammerhead shark, guanidine hydrochloride extraction, acetone precipitation and grading, enzymolysis, gel filtration chromatography, cell membrane chromatography purification and efficient liquid phase chromatography purification. The angiogenesis inhibiting factor can effectively inhibit angiogenesis of chick chorioallantoic membranes, and has an obvious inhibition function on expression of three angiogenesis promoting factors including the vascular endothelial cell growth factor, the basic fibroblast growth factor and the platelet-derived growth factor of lung cancer tissue of mice suffering from the Lewis lung cancer.

The invention discloses an application of a CDK7 targeting inhibitor in preparation of a medicine for treating cytokine release syndrome, which is verified by biochemical and animal model experiments as follows: (1) under proper concentration, the CDK7 targeting inhibitor inhibits the expression of super enhancers and transcription factors related to inflammatory factors such as stat1, IL-1 and IL-6, and thereby inflammatory signal pathways of immune cells such as macrophages, T cells and endothelial cells can be specifically regulated and controlled; (2) mouse death caused by acute inflammatory storm caused by bacterial or viral infection can be remarkably reduced, functional failure caused by inflammation of related organs is reduced, and obvious toxic and side effects are not found in the period. According to the results, the polypeptide has great significance in treatment of cytokine release syndrome caused by bacteria, viruses or immunotherapy.

The invention discloses a method to reprogram fibroblasts into Sertoli cells in vitro and application of the method. The method comprises the steps of introducing into fibroblasts, a fluorescent protein reporter system that specifically expresses in Sertoli cells; introducing a substance that increases NR5A1 protein expression and/or activity; adding G418, and culturing for 3-7 days; discarding anaqueous phase, adding a medium to culture fibroblasts, and continuing to culture for 3-7 days; isolating Sertoli cells from the culture system. Experiments prove that the cells prepared by the abovemethod fully attain the characteristics of Sertoli cells, such as ability to attract endothelial cells, ability to form lipid droplets, ability to interact with reproductive cells, ability to inhibitthe growth of lymphocytes and occurrence of interleukin, and ability of immune privilege and the like. The method has important applicable value in the fields, such as treatment of infertility, allograft, and cell therapy.

Provided herein are cell compositions useful for making artificial liver constructs. The cell composition my include, in combination, (a) hepatocyte cells, (b) Kuppfer cells, (c) hepatic stellate cells, (d) sinusoidal endothelial cells, and (e) cholangiocyte cells.

Provided is a peptide, which has an anti-inflammatory activity and an activity for promoting osteogenic differentiation, formed from the amino acid sequence selected from the group comprising the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3. And provided is a peptide, which has a hair growth promoting activity, formed from the amino acid sequence selected from the group comprising the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2. A peptide formed from the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, according to the present invention, consequently shows an anti-inflammatory activity by inhibiting an inflammatory cytokine expression and proliferation of inflammatory cells, and consequently promotes osteogenic differentiation by increasing phosphorylation of PI3K, Smad1, Smad5 and Smad8, which contribute to osteogenesis, and by increasing ALP, OPG and BSP expressions. And a peptide formed from the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, according to the present invention, consequently shows efficacy for preventing hair loss and promoting hair growth by promoting proliferation of hair follicle cells and human umbilical vein endothelial cells, increasing phosphorylation of EPK, increasing expressions of PI3K, β-catenin, IGF-1, KGF and Wnt3a which are proteins that contribute to hair growth, and reducing an expression of DKK-1 which is a hairless gene.